The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope

References

1. Amit A., Mariuzza R. A., Phillips S. E. V., Poljak R. J. 1986; Three-dimensional structure of an antigen-antibody complex at 2·8 Å resolution. Science 233:747–753
   [Google Scholar]
2. Broliden P.-A., Von Gegerfelt A., Clapham P., Rosen J., Fenyo E.-M., Wahren B., Broliden K. 1992; Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proceedings of the National Academy of Sciences, USA 89:461–465
   [Google Scholar]
3. Buratti E., Tisminetzky S. G., Scodeller E. S., Baralle F. E. 1996; Conformational display of two neutralizing epitopes of HIV-1 gp41 on the flock house virus capsid protein. Journal of Immunological Methods 197:7–18
   [Google Scholar]
4. Buratti E., Tisminetzky S. G., D’Agaro P., Baralle F. E. 1997; A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE. Journal of Virology 71:2457–2462
   [Google Scholar]
5. Chanh T. C., Dreesman G. R., Kanda P., Linette G. P., Sparrow J. T., Ho D. D., Kennedy R. C. 1986; Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO Journal 5:3065–3071
   [Google Scholar]
6. Cheinsong-Popov R., Callow D., Beddows S., Shaunak S., Wasi C., Kalcebu P., Gilks C., Petrascu I. V., Garaev M. M., Watts D. M., Constantine N. T., Weber J. N. 1992; Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to Env epitopes and relationship to neutralization. Journal of Infectious Diseases 165:256–261
   [Google Scholar]
7. Chen Y. H., Dierich M. P. 1996; Identification of a second site in HIV-1 gp41 mediating binding to cells. Immunology Letters 52:153–156
   [Google Scholar]
8. Dalgleish A. G., Chanh T. C., Kennedy R. C., Kanda P., Clapham P. R., Weiss R. A. 1988; Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 165:209–215
   [Google Scholar]
9. Davis D., Chaudhri B., Stephens D. M., Carne C. A., Willers C., Lachmann P. J. 1990; The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host’s previous exposure to similar epitopes on unrelated antigens. Journal of General Virology 71:1975–1983
   [Google Scholar]
10. Evans D. J., McKeating J., Meredith J. M., Burke K. L., Katrak K., John A., Ferguson M., Minor P. D., Weiss R. A., Almond J. W. 1989; An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339:385–388
    [Google Scholar]
11. Gallagher D. M. 1992; HIV/AIDS: the epidemic continues. Imprint 39:62
    [Google Scholar]
12. Ho D. D., McKeating J. A., Li X. L., Moudgil T., Daar E. S., Sun N.-C., Robinson J. E. 1991; Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. Journal of Virology 65:489–493
    [Google Scholar]
13. Jackson D. C., Poumbourios P., White D. O. 1988; Simultaneous binding of two monoclonal antibodies to epitopes separated in sequence by only three amino acid residues. Molecular Immunology 25:465–471
    [Google Scholar]
14. Kalyan N. K., Lee S. G., Wilhelm J., Pisano M. R., Hum W. T., Hsiao C. L., Davis A. R., Eichberg J. W., Robert-Guroff M., Hung P. P. 1994; Immunogenicity ofrecombinant influenza virus haemagglutinin-carrying peptides from the envelope protein of human immunodeficiency virus type 1. Vaccine 12:753–760
    [Google Scholar]
15. Kennedy R. C., Henkel R. D., Pauletti D., Allan J. S., Lee T. H., Essex M., Dreesman G. R. 1986; Antiserum to a synthetic peptide recognizes HTLV-III envelope glycoprotein. Science 231:1556–1559
    [Google Scholar]
16. McLain L., Dimmock N. J. 1994; Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. Journal of General Virology 75:1457–1460
    [Google Scholar]
17. McLain L., Porta C., Lomonossoff G. P., Durrani Z., Dimmock N. J. 1995; Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Research and Human Retroviruses 11:327–334
    [Google Scholar]
18. McLain L., Durrani Z., Wisniewski L. A., Porta C., Lomonossoff G. P., Dimmock N. J. 1996a; A plant virus-HIV-1 chimera stimulates antibodies that neutralize HIV-1. In Vaccine 96 pp. 311–316 Brown F., Burton D. R., Collier J., Mekalonos J., Norrby E. Edited by Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
19. McLain L., Durrani Z., Wisniewski L. A., Porta C., Lomonossoff G. P., Dimmock N. J. 1996b; Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine 14:799–810
    [Google Scholar]
20. Modrow S., Hahn B. H., Shaw G. M., Gallo R. C., Wong-Staal F., Wolf H. 1987; Computer assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates : prediction of antigenic epitopes in conserved and variable regions. Journal of Virology 61:570–578
    [Google Scholar]
21. Moore J. P. 1993; The reactivities of HIV-1⁺ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS Research and Human Retroviruses 9:209–217
    [Google Scholar]
22. Moore J. P., Sattentau Q. J., Wyatt R., Sodroski J. 1994a; Mapping the topology of the human immunodeficiency virus glycoprotein gp120 with a panel of monoclonal antibodies. Journal of Virology 68:469–484
    [Google Scholar]
23. Moore J. P., Cao Y., Conley A. J., Wyatt R., Robinson J., Gorny M. K., Zolla-Pazner S., Ho D. D., Koup R. A. 1994b; Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. Journal of Acquired Immune Deficiency Syndromes 7:332–339
    [Google Scholar]
24. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. 1993; A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology 67:6642–6647
    [Google Scholar]
25. Newton S. M. C., Joys T. M., Anderson S. A., Kennedy R. C., Hovi M. E., Stocker B. A. D. 1995; Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine. Research in Microbiology 146:203–216
    [Google Scholar]
26. Pincus S. H., Messer K. G., Schwartz D. H., Lewis G. K., Graham B. S., Blattner W. A., Fisher G. 1993; Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. Journal of Clinical Investigation 91:1987–1996
    [Google Scholar]
27. Pincus S. H., Messer K. G., Hu S.-L. 1994; Effect of non protective vaccination on antibody response to subsequent human immunodeficiency virus infection. Journal of Clinical Investigation 93:140–146
    [Google Scholar]
28. Sattentau Q. J., Zolla-Pazner S., Poignard P. 1995; Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206:713–717
    [Google Scholar]
29. Tisminetzky S. G., Scodeller E. A., Evangelista P., Chen Y., Schiappacassi M., Porro F., Bizik F., Zacchi T., Lunazzi G., Miertus S., Baralle F. E. 1994; Immunoreactivity of chimeric proteins carrying the HIV-1 epitope IGPGRAF: correlation between predicted conformation and antigenicity. FEBS Letters 353:1–4
    [Google Scholar]
30. Tsoukas C. M., Bernard N. F. 1994; Markers predicting progression of human immunodeficiency virus-related disease. Clinical Microbiology Reviews 7:14–28
    [Google Scholar]
31. Vella C., Minor P. D., Weller I. V. D., Jenkins O., Evans D., Almond J. 1991; Recognition of poliovirus/HIV chimaeras by antisera from individuals with HIV infection. AIDS 5:425–430
    [Google Scholar]
32. Vella C., Ferguson M., Dunn G., Meloen R., Langedijk H., Evans D., Minor P. D. 1993; Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. Journal of General Virology 74:2603–2607
    [Google Scholar]
33. Weiss R. A. 1993; How does HIV cause AIDS?. Science 260:1273–1279
    [Google Scholar]
34. Wilson I. A., Stanfield R. L. 1993; Antibody-antigen interactions. Current Opinion in Structural Biology 3:113–118
    [Google Scholar]